Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 1Active not recruiting 1

Sponsor Class

OTHER 5NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Thoracic 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Carcinoma, Renal Cell 11Pancreatic Neoplasms 4Multiple Myeloma 4Urinary Bladder Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Kidney Neoplasms 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Thymoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Mast-Cell 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2

Interventions

Carboplatin 43Paclitaxel 33Specimen Handling 15Taxes 14Cyclophosphamide 14Magnetic Resonance Spectroscopy 12Gemcitabine 12Biopsy 12Bevacizumab 12aldesleukin 11Immunoglobulin G 11Disulfides 11veliparib 9Topotecan 9Doxorubicin 9Cisplatin 9Docetaxel 8fludarabine 7olaparib 6liposomal doxorubicin 6Oxaliplatin 6Chemotherapy, Adjuvant 5talazoparib 4sargramostim 4pembrolizumab 4cediranib 4Nivolumab 4Fluorouracil 4Drug Therapy 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NIH × Ovarian Neoplasms × Sunitinib × Clear all
NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
6,452 enrolled 1 FDA
BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT00979992 2020-02-19

Sunitinib Malate in Treating Patients With Persistent or Recurrent Clear Cell Ovarian Cancer

National Cancer Institute (NCI)

Phase 2 Completed
35 enrolled 9 charts
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡